FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293858> ?p ?o ?g. }

• W4286293858 endingPage "e15124" @default.
• W4286293858 startingPage "e15124" @default.
• W4286293858 abstract "e15124 Background: Somatic chromosomal fusions involving ROS1 produce chimeric proteins that drive tumorigenesis and progression. Currently, ROS1-directed tyrosine kinase inhibitors (TKIs) are effective treatments for advanced non-small cell lung cancer (NSCLC) patients (pts) with ROS1 fusions. Except for NSCLC, Glioblastoma and spitzoid neoplasms, ROS1 fusions have been rarely reported in other cancers. Therefore, clarifying the patterns and frequency of ROS1 fusions in multi-cancer may help pts benefit from ROS1 inhibit therapy. Methods: To characterize the ROS1-fusion patterns in Chinese pts, we retrospectively analyzed the next-generation sequencing (NGS) data of 11,740 pts from 2017 to 2021. Results: In this study, a total of 12 ROS1 fusions were identified in this Chinese nonlung solid tumors cohort (12/11,740). Among them, the ROS1-fusion positive rate is 0.037% in colonrectal cancer pts (2/5,467), 0.13% in stomach cancer pts (3/2,268), 0.11% in liver cancer pts (2/1,774), 0.19% in kidney cancer pts (1/540), 0.21% in pancreatic cancer pts (2/966) and 0.28% in sarcoma pts (2/725). Particularly, we observed the coexistence of CD80- ROS1 and Intergenic- ROS1 in the same kidney cancer pt. Among ROS1 fusions described in this cohort, the frequency of known partners was 16.67%, and the frequency of unreported partners was 83.33%. Compared with NSCLC (1%̃2%), the ROS1 fusions are less frequent in the nonlung solid tumors (≤0.3%), and fusion partners are mostly unreported, which means that the efficacy of ROS1 TKIs in these solid tumor pts may be different from that in lung cancer. Therefore, more attention and in-depth research are needed in ROS1 fusion positive nonlung solid tumors, which have a low incidence and few cases, so as to bring clinical benefits to more pts. Conclusions: Through NGS, we identified ROS1 fusion patterns in non-lung solid tumors, most of which fusion partners are unreported, expanding the range of ROS1 fusions documented in tumors and providing potential for ROS1 TKIs in multiple tumors.[Table: see text]" @default.
• W4286293858 created "2022-07-21" @default.
• W4286293858 creator A5005239198 @default.
• W4286293858 creator A5009309112 @default.
• W4286293858 creator A5021714468 @default.
• W4286293858 creator A5025080382 @default.
• W4286293858 creator A5027311139 @default.
• W4286293858 creator A5076874028 @default.
• W4286293858 date "2022-06-01" @default.
• W4286293858 modified "2023-09-29" @default.
• W4286293858 title "Analysis of <i>ROS1</i> fusions in nonlung solid tumors." @default.
• W4286293858 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e15124" @default.
• W4286293858 hasPublicationYear "2022" @default.
• W4286293858 type Work @default.
• W4286293858 citedByCount "0" @default.
• W4286293858 crossrefType "journal-article" @default.
• W4286293858 hasAuthorship W4286293858A5005239198 @default.
• W4286293858 hasAuthorship W4286293858A5009309112 @default.
• W4286293858 hasAuthorship W4286293858A5021714468 @default.
• W4286293858 hasAuthorship W4286293858A5025080382 @default.
• W4286293858 hasAuthorship W4286293858A5027311139 @default.
• W4286293858 hasAuthorship W4286293858A5076874028 @default.
• W4286293858 hasConcept C121608353 @default.
• W4286293858 hasConcept C126322002 @default.
• W4286293858 hasConcept C143998085 @default.
• W4286293858 hasConcept C2775999482 @default.
• W4286293858 hasConcept C2776232967 @default.
• W4286293858 hasConcept C2776256026 @default.
• W4286293858 hasConcept C2779422266 @default.
• W4286293858 hasConcept C2781182431 @default.
• W4286293858 hasConcept C502942594 @default.
• W4286293858 hasConcept C71924100 @default.
• W4286293858 hasConceptScore W4286293858C121608353 @default.
• W4286293858 hasConceptScore W4286293858C126322002 @default.
• W4286293858 hasConceptScore W4286293858C143998085 @default.
• W4286293858 hasConceptScore W4286293858C2775999482 @default.
• W4286293858 hasConceptScore W4286293858C2776232967 @default.
• W4286293858 hasConceptScore W4286293858C2776256026 @default.
• W4286293858 hasConceptScore W4286293858C2779422266 @default.
• W4286293858 hasConceptScore W4286293858C2781182431 @default.
• W4286293858 hasConceptScore W4286293858C502942594 @default.
• W4286293858 hasConceptScore W4286293858C71924100 @default.
• W4286293858 hasIssue "16_suppl" @default.
• W4286293858 hasLocation W42862938581 @default.
• W4286293858 hasOpenAccess W4286293858 @default.
• W4286293858 hasPrimaryLocation W42862938581 @default.
• W4286293858 hasRelatedWork W1559620080 @default.
• W4286293858 hasRelatedWork W1592240224 @default.
• W4286293858 hasRelatedWork W1997505729 @default.
• W4286293858 hasRelatedWork W2006164250 @default.
• W4286293858 hasRelatedWork W2166589505 @default.
• W4286293858 hasRelatedWork W2332102550 @default.
• W4286293858 hasRelatedWork W2767181794 @default.
• W4286293858 hasRelatedWork W2775798067 @default.
• W4286293858 hasRelatedWork W2964989113 @default.
• W4286293858 hasRelatedWork W3201550227 @default.
• W4286293858 hasVolume "40" @default.
• W4286293858 isParatext "false" @default.
• W4286293858 isRetracted "false" @default.
• W4286293858 workType "article" @default.